Onco Actu du 15 novembre 2017

	2.6 Etiologie - Environnement
Monsanto, U.S. farm groups sue California over glyphosate warnings [Reuters] In the lawsuit, filed in federal court in California, Monsanto and groups representing corn, soy and wheat farmers reject that glyphosate causes cancer. They say the state’s requirement for warnings would force sellers of products containing the chemical to spread false information.
	5. Traitements
Science Surgery: ‘Is the one-size-fits-all treatment approach obsolete?’ [Cancer Research UK] “Ironically, the term ‘personalised therapy’ can mean something different to everyone,” says Fielding.
Alternate Driver of Treatment-Resistant Prostate Cancer Identified [NCI] If studies show that FGF signaling pathway inhibitors extend survival in men with androgen-independent metastatic prostate cancer that is dependent on FGF signaling, the long-term strategy might be to incorporate FGF inhibitors as part of first-line therapy for metastatic disease instead of waiting for androgen resistance to develop.
	5.10 Traitements - Essais
Navigating the new Clinical Trial Regulation with DIA [Pharmafile] For those stakeholders involved with clinical trials in Europe, the new Clinical Trial Regulation to be introduced in 2019 will have a dramatic impact. The aim of the change in regulation is to increase the efficiency of all trials in Europe, as well as promoting research while avoiding the duplication of clinical trials.
	5.12.1 Immunothérapies - partenariats
Seres teams with cancer heavyweights for microbiome-checkpoint inhibitor combination trial [FierceBiotech] In the randomized, placebo-controlled clinical trial, investigators at MD Anderson will assess the effect of giving SER-401 to patients with advanced metastatic melanoma who are being treated with an anti-PD-1 checkpoint inhibitor. SER-401 is a preclinical, orally-administered cocktail of live bacteria.
Biotech firms race to recruit good bugs in war on cancer [Reuters] Seres Chief Executive Roger Pomerantz told Reuters the aim was to start the randomized, placebo-controlled clinical trial in metastatic melanoma in 2018, evaluating the impact of giving a newly developed Seres microbiome drug alongside a PD-1 therapy.
	5.12.8 Immunothérapies - Economie
With $25M, Torque Aims for a More Targeted Cell Therapy for Cancer [Xconomy] The company has developed a way to attach to these cells drugs that can boost immune attack of tumors. These “deep-primed” T cells carry the immunomodulating drugs to the tumors, where they prompt an immune response that’s local and targeted to the tumor, rather than one that happens throughout the body, says Bart Henderson, CEO and co-founder of Torque.
	5.2.1 Pharma - Partenariats
In a Precision Step, Bayer Writes Loxo $400M Check for Two Cancer Drugs [Xconomy] At the American Society of Clinical Oncology’s (ASCO) annual meeting in June, Loxo reported that 78 percent of the 55 total patients in three separate clinical trials of larotrectinib responded to treatment, meaning their tumors at least partially shrunk.
Loxo Sells Bayer Rights To Rare Cancer Drug For More Than $1 Billion [Forbes] Over the next few years, the deal could result in Loxo receiving a total of $1 billion. But Loxo shares are down 5% in pre-market trading as investors balance these payments with Loxo deciding to give up full U.S. rights to sales from its lead medicine. (The company's shares are up 170% this year.)
Loxo's Good Deed Goes Punished [Bloomberg] Loxo's near-term acquisition prospects may have been dampened slightly. But its long-term potential is just as bright.
Loxo signs lucrative cancer drug deal with Bayer, but shares fall [Reuters] The deal, which includes Loxo’s follow-up drug LOXO-195, gives Bayer entry into the fledgling field of drugs that attack cancer based on genetics rather than the organ where the disease originates.
Loxo Oncology Announces Global Development and Commercialization Partnership with Bayer for Larotrectinib and LOXO-195 [Loxo] Loxo Oncology will lead global development activities and United States (U.S.) regulatory activities. Bayer will lead ex-U.S. regulatory activities, and worldwide commercial activities.
	5.2.3 Pharma - économie
San Diego’s stealthy Odonate surfaces with $173M IPO [EndPoints] Odonate plans to start enrolling for a Phase III study in metastatic breast cancer during the fourth quarter of 2017, and have data by 2020.
	5.3 Traitements - FDA, EMA, NICE...
EMA to work with stakeholders to improve the product information for EU medicines [EMA] The European Medicines Agency (EMA) has published an action plan to improve the product information (PI) for EU medicines, an information package for patients and healthcare professionals that accompanies every single medicine authorised in the EU and explains how it should be used and prescribed.
	5.3.4 Traitements - AMM (FDA, EMA)
Faslodex receives US FDA approval for the treatment of advanced breast cancer in combination with abemaciclib [AstraZeneca] The FDA approval is based on data from the Phase III MONARCH 2 trial, which met the study’s primary endpoint of PFS. The trial included 669 women with HR+, HER2- advanced breast cancer.
	5.7.1 SABCS-communiqués
Novartis presents new data at SABCS across broad range of breast cancer patient populations, combination treatments and lines of therapy [Novartis] Results from the Phase III MONALEESA-7 trial in premenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer will be presented for the first time in a late-breaker oral presentation.
	6. Lutte contre les cancers
Three charts on: brain cancer in Australia [The Conversation] The Australian government recently announced a A$100 million dollar medical research fund committed to doubling the survival rates and improving the quality of life of patients with brain cancer over the next ten years.
UK Biobank Supercharges Medicine with Gene Data on 500,000 Brits [MIT Technology Review] The July data release isn’t the culmination of the project. In fact, the data collecting will end only when the last volunteer has succumbed to dementia, cancer, or another cause of death.